Liquidia Corporation reported strong Q2 2026 results, with YUTREPIA net sales reaching $170.4 million, a 31% increase from the previous quarter. The company achieved its fourth consecutive quarter of increasing profitability, recording a net income of $74.7 million and adjusted EBITDA of $96.3 million. Growth was driven by nearly 5,900 unique patient prescriptions since launch, supported by 10 ongoing clinical studies. Based on this momentum, Liquidia is targeting annual revenues exceeding $1 billion by 2027.
